David S. Hong

发表

Predictors of spine metastases at initial presentation of pediatric brain tumor patients: a single-institution study

Summer S. Han, Samuel R. Falkson, J. Sayadi, 2022, Child's Nervous System.

Molecular characterization of breast cancer CTCs associated with brain metastasis

T. Tan, J. Thiery, Jenny C. Chang, 2017, Nature Communications.

Patterns of Failure, Toxicity, and Survival after Extrapleural Pneumonectomy and Hemithoracic Intensity-Modulated Radiation Therapy for Malignant Pleural Mesothelioma

D. Gomez, R. Komaki, Z. Liao, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study

F. Meric-Bernstam, L. Byers, F. Janku, 2023, npj Precision Oncology.

Five-Year Overall Survival with Ipilimumab and Stereotactic Ablative Radiotherapy for Metastatic Disease.

K. He, Chad Tang, Dawei Chen, 2023, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Neurosurgical management of vertebral lesions in pediatric chronic recurrent multifocal osteomyelitis: patient series.

D. Purger, L. Rinsky, Daphne Li, 2023, Journal of neurosurgery. Case lessons.

Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)

F. Meric-Bernstam, A. Lazar, C. Roland, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies

R. Vikram, F. Meric-Bernstam, A. Naing, 2023, NPJ precision oncology.

Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non–Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100

C. Dooms, R. Govindan, S. Ramalingam, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

1955P Survival benefits of larotrectinib in an integrated dataset of patients with TRK fusion cancer

A. Drilon, J. Berlin, B. Geoerger, 2020 .

Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC.

S. Digumarthy, G. Scagliotti, L. Landi, 2023, Cancer discovery.

PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.

J. Lee, R. Kurzrock, Vanda M. Stepanek, 2013, Cancer research.

First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumors

R. Kurzrock, A. Naing, D. Hong, 2014, Investigational New Drugs.

Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.

Razelle Kurzrock, J Jack Lee, Rajyalakshmi Luthra, 2014, Cell reports.

TITLE : Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors

Russo, P. Pauwels, R. Rosell, 2014 .

MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Non-Squamous Non-Small Cell Lung Cancer Progressing On/After Checkpoint Inhibitor Therapy or Chemotherapy.

C. Blakely, S. Gadgeel, D. Waterhouse, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results

A. Ghafoor, J. Tanyi, D. Oh, 2023, Nature Medicine.

P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy

J. Lee, R. Kurzrock, C. Warneke, 2013, Oncotarget.

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.

Razelle Kurzrock, Rajyalakshmi Luthra, Apostolia M Tsimberidou, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors

S. Piha-Paul, S. Welch, V. Subbiah, 2017, Investigational New Drugs.

Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study

B. Tuch, J. Lee, A. Shaw, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Circulating tumor and endothelial cells as pharmacodynamic biomarkers in a phase I clinical trial of intravenous bevacizumab in combination with escalating doses of oral cediranib for patients with advanced malignancies.

R. Kurzrock, A. Naing, J. Wheler, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer

G. Mills, Han-Yu Chuang, Jian-Bing Fan, 2017, Clinical Cancer Research.

STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.

J. Nemunaitis, R. Kurzrock, M. Jo, 2018, Journal of Immunotherapy for Cancer.

Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.

R. Kurzrock, A. Naing, J. Wheler, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immunotherapy-Based Early-Phase Clinical Trials.

R. Wolff, A. Naing, T. Yap, 2023, Journal of gastrointestinal cancer.

A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors

P. LoRusso, R. Kurzrock, A. Naing, 2013, Investigational New Drugs.

Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer

J. Vauthey, S. Kopetz, M. Overman, 2015, British Journal of Cancer.

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.

R. Kurzrock, F. Janku, A. Naing, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma

E. Shpall, D. Chihara, J. Westin, 2023, Blood Advances.

The prognostic significance of left ventricular ejection fraction in patients with advanced cancer treated in phase I clinical trials.

K. Hess, Y. Ye, R. Wolff, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA 1 compared with Clinical Outcomes of Patients with Advanced Cancers , " 2 3

F. Meric-Bernstam, Helen J. Huang, F. Janku, 2017 .

Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report

P. Fracasso, K. He, P. Kebriaei, 2023, Melanoma research.

Sotorasib (Soto) plus panitumumab (Pmab) and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 phase 1b safety and efficacy.

M. Fakih, T. Price, S. Siena, 2023, Journal of Clinical Oncology.

Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer

A. Drilon, J. Berlin, D. Hyman, 2020, Zeitschrift für Gastroenterologie.

Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial

M. Schuler, D. Hong, A. Delmonte, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.